Breakthrough research advances our understanding of placental dysfunction and pre-eclampsia
Pre-eclampsia is a clinical syndrome that complicates 2 – 8% of pregnancies worldwide and is the leading cause of perinatal mortality and morbidity1. Today, pre-eclampsia is characterized by the presence of new onset hypertension and proteinuria. However, both of these diagnostic signs are non-specific, appear late in the disease, and can be indications of other conditions2.
The pathophysiology of pre-eclampsia, leading to the appearance of these clinical signs, is caused by two stages; first, incomplete development of the placenta and, second, a maternal response to placental dysfunction.
Pre-eclampsia and its complications can have a variable or sudden evolution. Not all women who develop a complication have both the diagnostic signs3. The maternal circulating level of Placental Growth Factor (PlGF) is significantly lowered in women with preterm pre-eclampsia4 providing clinicians with greater confidence when managing women with suspected pre-eclampsia.
Alere Triage® PLGF is an aid in the diagnosis of preterm pre-eclampsia and prognosis of preterm delivery in women presenting with suspected pre-eclampsia before 35 weeks.
1. Steegers, E. et al. Pre-eclampsia. The Lancet. 1 July 2010.
2. Sibai et al. Pre-eclampsia. Lancet. 2005.
3. Barton. Mild gestational hypertension remote from term; progression and outcome. AJOG, 2001.
4. Levine R, et al. (2004) Circulating Angiogenic Factors and the Risk of Preeclampsia. New England Journal of Medicine 350:7.